These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36513866)

  • 21. Polyphenol Metabolite Pyrogallol-
    Santos DF; Pais M; Santos CN; Silva GA
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The interaction between the renin-angiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascularization in diabetes.
    Wilkinson-Berka JL; Kelly DJ; Gilbert RE
    J Vasc Res; 2001; 38(6):527-35. PubMed ID: 11740151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress.
    Caldwell RB; Bartoli M; Behzadian MA; El-Remessy AE; Al-Shabrawey M; Platt DH; Liou GI; Caldwell RW
    Curr Drug Targets; 2005 Jun; 6(4):511-24. PubMed ID: 16026270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy.
    Kuiper EJ; Van Nieuwenhoven FA; de Smet MD; van Meurs JC; Tanck MW; Oliver N; Klaassen I; Van Noorden CJ; Goldschmeding R; Schlingemann RO
    PLoS One; 2008 Jul; 3(7):e2675. PubMed ID: 18628999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.
    Saishin Y; Saishin Y; Takahashi K; Lima e Silva R; Hylton D; Rudge JS; Wiegand SJ; Campochiaro PA
    J Cell Physiol; 2003 May; 195(2):241-8. PubMed ID: 12652651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. (Pro)renin receptor: Involvement in diabetic retinopathy and development of molecular targeted therapy.
    Kanda A; Ishida S
    J Diabetes Investig; 2019 Jan; 10(1):6-17. PubMed ID: 29575757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathophysiology and pharmacological targets of VEGF in diabetic macular edema.
    Fogli S; Mogavero S; Egan CG; Del Re M; Danesi R
    Pharmacol Res; 2016 Jan; 103():149-57. PubMed ID: 26607863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alteration of growth factors and neuronal death in diabetic retinopathy: what we have learned so far.
    Whitmire W; Al-Gayyar MM; Abdelsaid M; Yousufzai BK; El-Remessy AB
    Mol Vis; 2011 Jan; 17():300-8. PubMed ID: 21293735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy.
    Arrigo A; Aragona E; Bandello F
    Ann Med; 2022 Dec; 54(1):1089-1111. PubMed ID: 35451900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy.
    Endo M; Yanagisawa K; Tsuchida K; Okamoto T; Matsushita T; Higuchi M; Matsuda A; Takeuchi M; Makita Z; Koike T
    Horm Metab Res; 2001 May; 33(5):317-22. PubMed ID: 11440280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of the vascular endothelial growth factor isoforms in retinal angiogenesis and DiGeorge syndrome.
    Stalmans I
    Verh K Acad Geneeskd Belg; 2005; 67(4):229-76. PubMed ID: 16334858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy.
    Mathews MK; Merges C; McLeod DS; Lutty GA
    Invest Ophthalmol Vis Sci; 1997 Dec; 38(13):2729-41. PubMed ID: 9418725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes.
    Gilbert RE; Vranes D; Berka JL; Kelly DJ; Cox A; Wu LL; Stacker SA; Cooper ME
    Lab Invest; 1998 Aug; 78(8):1017-27. PubMed ID: 9714188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VEGF as a Survival Factor in Ex Vivo Models of Early Diabetic Retinopathy.
    Amato R; Biagioni M; Cammalleri M; Dal Monte M; Casini G
    Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3066-76. PubMed ID: 27286364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chlorogenic acid attenuates diabetic retinopathy by reducing VEGF expression and inhibiting VEGF-mediated retinal neoangiogenesis.
    Mei X; Zhou L; Zhang T; Lu B; Sheng Y; Ji L
    Vascul Pharmacol; 2018 Feb; 101():29-37. PubMed ID: 29146180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory.
    Romero-Aroca P; Baget-Bernaldiz M; Pareja-Rios A; Lopez-Galvez M; Navarro-Gil R; Verges R
    J Diabetes Res; 2016; 2016():2156273. PubMed ID: 27761468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of vascular endothelial growth factor-A
    Morawietz H; Frenzel A; Mieting A; Goettsch W; Valtink M; Roehlecke C; Jászai J; Funk RHW; Becker KA; Engelmann K
    Ther Apher Dial; 2022 Dec; 26 Suppl 1():29-34. PubMed ID: 36468302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VEGF promotes diabetic retinopathy by upregulating the PKC/ET/NF-κB/ICAM-1 signaling pathway.
    Zhang M; Zhou M; Cai X; Zhou Y; Jiang X; Luo Y; Hu Y; Qiu R; Wu Y; Zhang Y; Xiong Y
    Eur J Histochem; 2022 Oct; 66(4):. PubMed ID: 36305269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poly(ADP-ribose) Polymerase-1: An Update on Its Role in Diabetic Retinopathy.
    Sun J; Chen L; Chen R; Lou Q; Wang H
    Discov Med; 2021; 32(165):13-22. PubMed ID: 35219352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF.
    Poulaki V; Qin W; Joussen AM; Hurlbut P; Wiegand SJ; Rudge J; Yancopoulos GD; Adamis AP
    J Clin Invest; 2002 Mar; 109(6):805-15. PubMed ID: 11901189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.